In a twist that could help big pharma’s cause, marketers of generic drugs and biosimilars have joined the fight against provisions in the Build Back Better bill that would empower the Health and Human Services Department to negotiate the prices of certain high-cost, single source drugs that have been on the market long enough for their initial period of exclusivity to expire.
Strange Bedfellows: Generics Firms Join Big Pharma In Opposing Price Negotiation Legislation
Concerns that Medicare drug price negotiation provisions in the Build Back Better legislation would upend the generic and biosimilar industries might resonate with legislators more than complaints from branded drug companies.
